17 research outputs found
A Novel Classification of Lung Cancer into Molecular Subtypes
The remarkably heterogeneous nature of lung cancer has become more apparent over the last decade. In general, advanced lung cancer is an aggressive malignancy with a poor prognosis. The discovery of multiple molecular mechanisms underlying the development, progression, and prognosis of lung cancer, however, has created new opportunities for targeted therapy and improved outcome. In this paper, we define “molecular subtypes” of lung cancer based on specific actionable genetic aberrations. Each subtype is associated with molecular tests that define the subtype and drugs that may potentially treat it. We hope this paper will be a useful guide to clinicians and researchers alike by assisting in therapy decision making and acting as a platform for further study. In this new era of cancer treatment, the ‘one-size-fits-all’ paradigm is being forcibly pushed aside—allowing for more effective, personalized oncologic care to emerge
Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
Abstract
Background
Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres.
Methods
This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries.
Results
In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia.
Conclusion
This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries
Primary central nervous system lymphoma: A profile of 26 cases from western India
Background : Primary central nervous system (CNS) lymphoma (PCNSL) is a
rare malignant non-Hodgkin′s lymphoma and it accounts for 1% of
all intracranial tumors. Only a few PCNSL studies have been reported
from India, and studies on prognostic factors determining outcome, or
evaluation of the response to currently accepted treatment, are
lacking. Aims : This study attempts to further delineate the clinical,
radiological and pathological profile of PCNSL in India, to evaluate
response to treatment and to assess usefulness of the International
Extranodal Lymphoma Study Group (IELSG) score. Settings and Design :
All patients with pathologically proven PCNSL admitted over three years
at a large tertiary care institution were studied. Materials and
Methods : Clinical features, IELSG prognostic score, imaging and
pathological features, and response to treatment were evaluated.
Results were analyzed using χ 2 test. Results : Of 26 patients
found, all except two were immunocompetent. Median age at diagnosis was
59 years. Focal deficits (76.9%) and neuropsychiatric symptoms (57.6%)
were the commonest presenting complaints. Except for one case, at least
some contrast enhancement was seen in brain lesions of all patients.
Pathological studies showed high grade diffuse large B-cell (DLBCL)
histology in 96.2% of patients. Of 22 patients who received
methotrexate (MTX) based chemotherapy with/without radiotherapy; six
died, with a response rate of 72.7%. Median survival was 10 months.
Median follow-up duration was 14.5 months. Four patients developed
treatment-related cognitive decline. All six patients with IELSG score
of 4/5 died, while all 16 patients with a score of 0-3 survived.
Conclusions : PCNSL presents most commonly in the sixth decade with
focal neurological deficit, behavioral symptoms and cognitive decline.
High grade DLBCL is the commonest histological subtype. Steroids should
ideally be withheld until biopsy as they may confound the diagnosis.
Most immunocompetent patients respond well to high dose MTX-based
chemotherapy with/without radiation. High IELSG scores correlate with
worse prognosis in patients with PCNS
Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer
Optimization of adjuvant systemic therapy in women with early-stage hormone receptor-positive breast cancer includes the consideration of chemotherapy and duration of hormone therapy. Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). Expert oncologist discussed on the duration of adjuvant hormonal therapy for improvement of OS and quality of life of breast cancer patients by providing reduction in recurrence and mortality. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists
Management of primary and metastatic triple negative breast cancer: Perceptions of oncologists from India
Background: In order to document the understanding of current evidence
for the management of triple negative breast cancer and application of
this knowledge in daily practice, we conducted an interactive survey of
practicing Indian oncologists. Materials and Methods: A core group of
academic oncologists devised two hypothetical triple negative cases
(metastatic and early breast cancer, respectively) and multiple choice
options under different clinical circumstances. The respondents were
practicing oncologists in different Indian cities who participated in
either an online survey or a meeting. The participants electronically
chose their preferred option based on their everyday practice. Results:
A total of 152 oncologists participated. Just over half (53.8%)
preferred taxane based chemotherapy as first-line chemotherapy in the
metastatic setting. In the adjuvant setting, a taxane regimen was
chosen by 61%. Over half of respondents (52.6%) underestimated the
baseline survival of a patient with node positive triple-negative tumor
and 18.9% overestimated this survival compared to the estimate of the
Adjuvant! program. Discussion: This data offers insight into the
perceptions and practice of a diverse cross-section of practicing
oncologists in India with respect to their therapeutic choices in
metastatic and adjuvant settings in triple negative breast cancer